Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

RhIL-15 with Dinutuximab, Irinotecan and Temozolomide for the Treatment of Children and Young Adults with Relapsed or Refractory Neuroblastoma

Trial Status: active

This phase I trial tests the safety, side effects and best dose of recombinant human (rh) interleukin (IL)-15 when given with dinutuximab, irinotecan and temozolomide for the treatment of children and young adults with neuroblastoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). RhIL-15 is a man-made version of a small protein (cytokine) that is naturally produced in the body by certain white blood cells and increases the activity and strength of the immune system and may also activate immune cells to kill neuroblastoma cells. Dinutuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving rhIL-15 with dinutuximab, irinotecan and temozolomide may be safe, tolerable and/or effective in treating patients with children and young adults with relapsed or refractory neuroblastoma.